



Prescription Pharmaceutical Products

PRODUCT	INDICATION ^{1,2}	TERRITORY ³					PARTNER
		Canada	Brazil	Argentina	Colombia	Mexico	
Oncology/Hematology							
Minjuvi [®]	Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)	N/A ⁴	Q1-24	Submitted	Submitted	Submitted	Incyte
Pemazyre [®]	Metastatic cholangiocarcinoma	N/A ⁴	Submitted	Submitted	Submitted	Submitted	Incyte
Akynzeo [®]	Prevention of chemotherapy-induced acute and delayed nausea and vomiting	Q4-22	Q3-22	Q3-22	N/A ⁴	N/A ⁴	Helsinn
Aloxi [®]	Prevention of acute nausea and vomiting associated with moderately and highly emetogenic cancer chemotherapy	Q4-22	N/A ⁴	N/A ⁴	N/A ⁴	N/A ⁴	Helsinn
Tavalisse [®] (fostamatinib)	Treatment of chronic immune thrombocytopenia	N/A ⁴	Submitted	Pre-registration	Submitted	Submitted	Rigel
Trelstar [®]	Advanced prostate cancer	Q2-20	N/A ⁴	N/A ⁴	N/A ⁴	N/A ⁴	Debiopharm
Vidaza [®]	Myelodysplastic syndrome	N/A ⁴	Q2-10	N/A ⁴	N/A ⁴	N/A ⁴	BMS
Abraxane [®]	Metastatic pancreatic cancer	N/A ⁴	Q4-17	N/A ⁴	N/A ⁴	N/A ⁴	BMS
Halaven [®]	Metastatic breast cancer and soft tissue sarcoma	N/A ⁴	Q4-17	Q4-19	Q2-22	N/A ⁴	Eisai
Lenvima [®]	Differentiated thyroid cancer and unresectable hepatocellular carcinoma	N/A ⁴	Q4-17		Q1-22	N/A ⁴	Eisai
Lenvima [®]	Advanced renal cell cancer	N/A ⁴	Q4-17			N/A ⁴	Eisai
BGx							
Ladevina [®]	Multiple myeloma; myelodysplastic syndrome			2011	Q3-19		Own
Ladevina [®]	Mantle Cell Lymphoma; follicular lymphoma			2011			Own
Zyvalix [®]	Metastatic prostate cancer			2014	Q2-18		Own
Karfib [®]	Relapsed or refractory multiple myeloma			Q4-19	Approved		Own
Leprid [®]	Palliative treatment of advanced prostate cancer			2007			Own
Rembre [®]	Chronic myeloid leukemia			2013	Q1-22		Own
Palbocil [®] , Bapocil [®]	Breast cancer			Q1-23	Submitted		Own
Xetrane [®]	Multiple myeloma			Q2-19	Submitted		Own
Xetrane [®]	AIDS-related Kaposi sarcoma			Q2-22			Own

¹ The products listed as "Pre-registration" have not yet been submitted for regulatory review and products in "Submitted" are currently under regulatory review. The indication for all products classified as "Pre-registration" or "Submitted" is the anticipated indication upon regulatory approval.

² The products listed as "Approved" have been approved by regulatory authorities but not yet commercially launched.

³ The products with an associated date are currently marketed by Knight in the respective territory. The information provided represents the date when the product was launched by Knight or when it was acquired or in-licensed by Knight if such products had existing sales.

⁴ Knight does not have the commercial rights in these territories.



PRODUCT	INDICATION ^{1,2}	TERRITORY ³					PARTNER
		Canada	Brazil	Argentina	Colombia	Mexico	
Infectious Diseases							
Ambisome®	Invasive fungal infection	N/A ⁴	1997	N/A ⁴	N/A ⁴	N/A ⁴	Gilead
Cresemba®	Invasive fungal infection	N/A ⁴	Q2-20	Q3-19	Q3-19	Q2-19	Basilea
Impavido®	Leishmaniasis						Own
BGx							
Dolufevir®	HIV infection			Q2-21			Own
Other Specialty							
Exelon®	Symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease	Q2-21	Q2-21	Q2-21	Q2-21	Q2-21	Own
Ibsrela®	IBS-C	Q1-21	N/A ⁴	N/A ⁴	N/A ⁴	N/A ⁴	Ardelyx
Salofalk®	Ulcerative colitis	N/A ⁴	N/A ⁴	2007	Pre-2019	N/A ⁴	Dr. Falk
Ursofalk®	Primary biliary cirrhosis	N/A ⁴	N/A ⁴	2007	Pre-2019	N/A ⁴	Dr. Falk
Imvexxy®	Moderate-to-severe dyspareunia	Q1-24	N/A ⁴	N/A ⁴	N/A ⁴	N/A ⁴	TXMD
Bijuva®	Moderate-to-severe vasomotor symptoms due to menopause	Q1-24	N/A ⁴	N/A ⁴	N/A ⁴	N/A ⁴	TXMD
BGx							
Fibridoner®	Idiopathic pulmonary fibrosis			2017			Own

¹ The products listed as "Pre-registration" have not yet been submitted for regulatory review and products in "Submitted" are currently under regulatory review. The indication for all products classified as "Pre-registration" or "Submitted" is the anticipated indication upon regulatory approval.

² The products listed as "Approved" have been approved by regulatory authorities but not yet commercially launched.

³ The products with an associated date are currently marketed by Knight in the respective territory. The information provided represents the date when the product was launched by Knight or when it was acquired or in-licensed by Knight if such products had existing sales.

⁴ Knight does not have the commercial rights in these territories.



Pipeline and Products in Early Launch Stage

The Company expects that its pipeline and products in early launch stage could achieve total revenues of over \$150,000,000 combined in their peak years. The products in early launch stage are within three years from the commercial launch date on a country by country basis.

PRODUCT	INDICATION OR THERAPEUTIC AREA ^{1,2}	TERRITORY ³					LAUNCH / EXPECTED LAUNCH YEAR
		Canada	Brazil	Argentina	Colombia	Mexico	
Oncology/Hematology							
Minjuvi® (tafasitamab)	Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)	N/A ⁴	Q1-24	Submitted	Submitted	Submitted	2024 -2026
Pemigatinib	Metastatic cholangiocarcinoma	N/A ⁴	Submitted	Submitted	Submitted	Submitted	2025-2026
Fostamatinib	Treatment of chronic immune thrombocytopenia	N/A ⁴	Submitted	Pre-registration	Submitted	Submitted	2025-2026
Bapocil®¹	Breast Cancer				Submitted		2025
Xetrane®¹	Multiple myeloma				Submitted		2025
Karfib®¹	Relapsed or refractory multiple myeloma				Approved		2025
Rembre®¹	Chronic myeloid leukemia				Q1-22		N/A
O501¹	Oncology/Hematology			Submitted			2025
O502¹	Oncology/Hematology			Submitted			2025
H401	Oncology/Hematology	N/A ⁴	Development	N/A ⁴	Development	Development	2028
H402	Oncology/Hematology		Development				2028 - 2029
Other Specialty							
Imvexxy®	Moderate-to-severe dyspareunia	Q1-24	N/A ⁴	N/A ⁴	N/A ⁴	N/A ⁴	2024
Bijuva®	Moderate-to-severe vasomotor symptoms due to menopause	Q1-24	N/A ⁴	N/A ⁴	N/A ⁴	N/A ⁴	2024
IPX203	Parkinson's disease	Pre-registration	Pre-registration	Pre-registration	Pre-registration	Pre-registration	2027-2028
Qelbree™	Attention-Deficit Hyperactivity Disorder (ADHD)	Pre-registration	N/A ⁴	N/A ⁴	N/A ⁴	N/A ⁴	2026-2027
Jornay PM™	Attention-Deficit Hyperactivity Disorder (ADHD)	Submitted				Pre-registration	2025-2028
C401 (Neurology)	Other Specialty				Submitted		2025 - 2026
C402/403 (Neurology)	Other Specialty	N/A ⁴	Submitted		Development	Pre-registration	2026 - 2027

¹ The products listed as "Pre-registration" have not yet been submitted for regulatory review and products in "Submitted" are currently under regulatory review. The indication for all products classified as "Pre-registration" or "Submitted" is the anticipated indication upon regulatory approval.

² The products listed as "Approved" have been approved by regulatory authorities but not yet commercially launched.

³ The products with an associated date are currently marketed by Knight in the respective territory. The information provided represents the date when the product was launched by Knight or when it was acquired or in-licensed by Knight if such products had existing sales.

⁴ Knight does not have the commercial rights in these territories.